人体中甲氨蝶呤的血清、泪液和唾液浓度。
Serum, tear and salivary concentrations of methotrexate in man.
作者信息
Steele W H, Stuart J F, Whiting B, Lawrence J R, Calman K C, McVie J G, Baird G M
出版信息
Br J Clin Pharmacol. 1979 Feb;7(2):207-11. doi: 10.1111/j.1365-2125.1979.tb00923.x.
Abstract
- Methotrexate handling has been studied in four patients with psoriasis and eleven patients with neoplastic disease. 2. Methotrexate levels in serum, tears and saliva were measured by radioimmunoassay while protein binding studies were performed by continuous ultrafiltration. 3. There was a close correlation between methotrexate concentrations in tears and serum (P less than 0.001, r = 0.714). Parotid salivary and serum methotrexate levels were similarly correlated (P less than 0.001, r = 0.557) but not mixed salivary and serum levels (P greater than 0.1, r = 0.232). 4. The mean protein binding was 95.11% +/- 2.26 (s.d.) while the ratio of methotrexate levels in tears to the free serum methotrexate level was 1:1.04. The corresponding parotid salivary level: free serum level ratio was 1:18.11. 5. No relationship could be determined between the methotrexate levels in tears and conjunctivitis observed in some of the patients under study.
摘要
- 已对4例银屑病患者和11例肿瘤疾病患者的甲氨蝶呤处置情况进行了研究。2. 采用放射免疫分析法测定血清、泪液和唾液中的甲氨蝶呤水平，同时通过连续超滤进行蛋白结合研究。3. 泪液和血清中的甲氨蝶呤浓度之间存在密切相关性（P<0.001，r=0.714）。腮腺唾液和血清中的甲氨蝶呤水平也有类似的相关性（P<0.001，r=0.557），但混合唾液和血清水平之间无相关性（P>0.1，r=0.232）。4. 平均蛋白结合率为95.11%±2.26（标准差），而泪液中甲氨蝶呤水平与游离血清甲氨蝶呤水平之比为1:1.04。腮腺唾液水平与游离血清水平的相应比值为1:18.11。5. 在一些研究对象中观察到的泪液中甲氨蝶呤水平与结膜炎之间未发现相关性。
相似文献
1
Serum, tear and salivary concentrations of methotrexate in man.人体中甲氨蝶呤的血清、泪液和唾液浓度。
Br J Clin Pharmacol. 1979 Feb;7(2):207-11. doi: 10.1111/j.1365-2125.1979.tb00923.x.
2
The free fraction of valproic acid in tears, saliva, and cerebrospinal fluid.
Epilepsia. 1982 Feb;23(1):23-6. doi: 10.1111/j.1528-1157.1982.tb05049.x.
3
Methotrexate concentrations in serum and saliva in children treated with high doses of methotrexate i.v.接受大剂量静脉注射甲氨蝶呤治疗的儿童血清和唾液中甲氨蝶呤的浓度
J Clin Chem Clin Biochem. 1989 Apr;27(4):228-9.
4
Comparison of methods for determining unbound theophylline concentrations.
Ther Drug Monit. 1986;8(1):42-6. doi: 10.1097/00007691-198603000-00009.
5
Methotrexate serum and saliva concentrations in patients.患者体内甲氨蝶呤的血清和唾液浓度。
Int J Clin Pharmacol Ther Toxicol. 1981 Sep;19(9):381-5.
6
The protein binding of methotrexate in the serum of patients with neoplastic disease.甲氨蝶呤在肿瘤疾病患者血清中的蛋白结合情况。
Cancer Chemother Pharmacol. 1981;7(1):61-4. doi: 10.1007/BF00258215.
7
Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay.通过放射免疫分析法测定混合唾液、腮腺唾液、颌下唾液及血清中的苯妥英浓度。
Br J Clin Pharmacol. 1977 Apr;4(2):185-91. doi: 10.1111/j.1365-2125.1977.tb00692.x.
8
The protein binding of methotrexate by the serum of normal subjects.
Eur J Clin Pharmacol. 1979 Jun 12;15(5):363-6. doi: 10.1007/BF00558441.
9
A rapid and specific radioimmunoassay for methotrexate.一种快速且特异的甲氨蝶呤放射免疫测定法。
Cancer Res. 1975 Jun;35(6):1407-10.
10
Salivary thyroxine as an estimate of free thyroxine: concise communication.唾液甲状腺素作为游离甲状腺素的一种评估指标：简要通讯
J Nucl Med. 1983 Aug;24(8):700-2.
引用本文的文献
1
Real-World Outcomes of Allogeneic Immunosafe Plasma Rich in Growth Factors Eye Drops for Refractory Ocular Surface Diseases: A Prospective Observational Study.富含生长因子的同种异体免疫安全血浆滴眼液治疗难治性眼表疾病的真实世界疗效：一项前瞻性观察研究。
Ophthalmol Ther. 2025 Jul 25. doi: 10.1007/s40123-025-01211-1.
2
Prevention of Taste Alterations in Patients with Cancer Receiving Paclitaxel- or Oxaliplatin-Based Chemotherapy-A Pilot Trial of Cannabidiol.癌症患者接受紫杉醇或奥沙利铂化疗时味觉改变的预防-大麻二酚的初步试验。
Nutrients. 2023 Jul 1;15(13):3014. doi: 10.3390/nu15133014.
3
Clinical pharmacokinetics of commonly used anticancer drugs.常用抗癌药物的临床药代动力学
Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002.
4
Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions.甲氨蝶呤输注24小时后血清、唾液和汗液中甲氨蝶呤浓度之间缺乏相关性。
Br J Clin Pharmacol. 1987 Oct;24(4):537-41. doi: 10.1111/j.1365-2125.1987.tb03208.x.
5
Therapeutic drug monitoring in saliva. An update.唾液中的治疗药物监测。最新进展。
Clin Pharmacokinet. 1992 Nov;23(5):365-79. doi: 10.2165/00003088-199223050-00003.
本文引用的文献
1
Effect of aminopterin on epithelial tissues.氨甲蝶呤对上皮组织的作用。
AMA Arch Derm Syphilol. 1951 Dec;64(6):688-99. doi: 10.1001/archderm.1951.01570120023004.
2
PARENTERAL METHOTREXATE IN PSORIASIS.银屑病的胃肠外甲氨蝶呤治疗
Arch Dermatol. 1964 Apr;89:550-6.
3
4
Intermittent high dose oral methotrexate therapy in psoriasis.
Br J Dermatol. 1970 Jan;82(1):65-9. doi: 10.1111/j.1365-2133.1970.tb02194.x.
5
The effect of organic acids on renal clearance of methotrexate in man.
Clin Pharmacol Ther. 1969 Nov-Dec;10(6):849-57. doi: 10.1002/cpt1969106849.
6
Prolonged intravenous methotrexate therapy in the treatment of acute leukemia and solid tumors.
Cancer Res. 1970 Aug;30(8):2132-8.
7
Biochemical and pathophysiological rationale for amethopterin in psoriasis.
Ann N Y Acad Sci. 1971 Nov 30;186:452-66. doi: 10.1111/j.1749-6632.1971.tb47001.x.
8
Application of salivary salicylate data to biopharmaceutical studies of salicylates.唾液水杨酸数据在水杨酸盐生物制药研究中的应用。
J Pharm Sci. 1972 Aug;61(8):1219-22. doi: 10.1002/jps.2600610810.
9
Relationship between theophylline concentration in plasma and saliva of man.
Clin Pharmacol Ther. 1974 May;15(5):454-60. doi: 10.1002/cpt1974155454.
10
Measurement of drug displacement by continuous ultrafiltration.
J Pharm Sci. 1974 Feb;63(2):249-52. doi: 10.1002/jps.2600630215.
Zotero 插件